Wall Street brokerages expect Surgery Partners Inc (NASDAQ:SGRY) to announce $432.00 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Surgery Partners’ earnings. The lowest sales estimate is $429.23 million and the highest is $434.27 million. Surgery Partners posted sales of $288.35 million in the same quarter last year, which suggests a positive year-over-year growth rate of 49.8%. The company is expected to announce its next quarterly earnings report on Tuesday, August 14th.
According to Zacks, analysts expect that Surgery Partners will report full-year sales of $1.77 billion for the current fiscal year, with estimates ranging from $1.75 billion to $1.79 billion. For the next fiscal year, analysts forecast that the company will post sales of $1.89 billion per share, with estimates ranging from $1.89 billion to $1.91 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Surgery Partners.
Surgery Partners (NASDAQ:SGRY) last issued its quarterly earnings results on Wednesday, May 9th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). Surgery Partners had a negative return on equity of 1.90% and a negative net margin of 5.13%. The business had revenue of $417.37 million for the quarter, compared to analysts’ expectations of $410.79 million. During the same period in the prior year, the company earned ($0.06) EPS. The company’s revenue for the quarter was up 45.8% compared to the same quarter last year.
A number of research firms have recently commented on SGRY. BidaskClub upgraded Surgery Partners from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 16th. ValuEngine downgraded Surgery Partners from a “hold” rating to a “sell” rating in a report on Tuesday, May 22nd. Zacks Investment Research upgraded Surgery Partners from a “sell” rating to a “hold” rating in a report on Friday, April 6th. Finally, Stifel Nicolaus dropped their price objective on Surgery Partners from $17.00 to $15.00 and set a “sell” rating for the company in a report on Tuesday, April 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the stock. Surgery Partners currently has a consensus rating of “Hold” and an average target price of $18.29.
Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in Surgery Partners by 0.5% in the 4th quarter. BlackRock Inc. now owns 1,306,021 shares of the company’s stock valued at $15,804,000 after purchasing an additional 7,029 shares in the last quarter. MetLife Investment Advisors LLC acquired a new stake in Surgery Partners in the 1st quarter valued at $164,000. Schwab Charles Investment Management Inc. increased its holdings in Surgery Partners by 11.1% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 99,333 shares of the company’s stock valued at $1,704,000 after purchasing an additional 9,926 shares in the last quarter. We Are One Seven LLC acquired a new stake in Surgery Partners in the 4th quarter valued at $138,000. Finally, GSA Capital Partners LLP acquired a new stake in Surgery Partners in the 1st quarter valued at $222,000. Institutional investors and hedge funds own 97.59% of the company’s stock.
SGRY stock opened at $16.55 on Friday. The firm has a market cap of $758.15 million, a PE ratio of -19.70 and a beta of 1.83. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.72 and a quick ratio of 1.55. Surgery Partners has a 52 week low of $7.10 and a 52 week high of $24.05.
Surgery Partners Company Profile
Surgery Partners, Inc, through its subsidiaries, operates surgical facilities in the United States. The company operates through three segments: Surgical Facility Services, Ancillary Services, and Optical Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management.
Get a free copy of the Zacks research report on Surgery Partners (SGRY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.